Skip to main content

Table 5 Differences between therapeutic classes regarding the frequency of the “Not for Generic Substitution” mention use

From: Factors influencing the use of the “not for generic substitution” mention for prescriptions in primary care: a survey with general practitioners

Therapeutic class NGS mention use
Never (0%) Rarely (1–24%) Sometimes (25–49%) Often (50–74%) Very often/always (75–100%)
Thyroid hormones – n, % 21 (7.6) 30 (10.8) 30 (10.8) 62 (22.4) 134 (48.4)
Antiepileptic drugs – n, % 31 (11.2) 51 (18.4) 48 (17.3) 68 (24.6) 79 (28.5)
Antiplatelet agents – n, % 45 (16.2) 110 (39.7) 40 (14.4) 60 (21.7) 22 (7.9)
Proton pump inhibitors – n, % 74 (26.7) 117 (42.2) 40 (14.4) 38 (13.7) 8 (2.9)
Neuroleptics – n, % 95 (34.3) 107 (38.6) 44 (15.9) 25 (9.0) 6 (2.2)
Oral antidiabetic drugs– n, % 85 (30.7) 115 (41.5) 48 (17.3) 23 (8.3) 6 (2.2)
Statins – n, % 88 (31.8) 124 (44.8) 38 (13.7) 22 (7.9) 5 (1.8)
Antidepressants – n, % 74 (26.7) 117 (42.2) 57 (20.6) 25 (9.0) 4 (1.4)
Hypnotic drugs – n, % 80 (28.9) 125 (45.1) 40 (14.4) 29 (10.5) 3 (1.1)
Angiotensin converting enzyme inhibitors/Angiotensin II receptor blockers – n, % 81 (29.2) 120 (43.3) 48 (17.3) 25 (9.0) 3 (1.1)
Step II-III analgesics – n, % 106 (38.3) 109 (39.4) 47 (17.0) 12 (4.3) 3 (1.1)
Diuretics – n, % 106 (38.3) 123 (44.4) 31 (11.2) 15 (5.4) 2 (0.7)
Antispasmodic drugs – n, % 139 (50.2) 96 (34.7) 30 (10.8) 10 (3.6) 2 (0.7)
Anti-inflammatory drugs (Nonsteroidal and steroidal) – n, % 118 (42.6) 108 (39.0) 40 (14.4) 9 (3.2) 2 (0.7)
Beta blockers – n, % 88 (31.8) 128 (46.2) 36 (13.0) 24 (8.7) 1 (0.4)
Antibiotics – n, % 107 (38.6) 108 (39.0) 39 (14.1) 22 (7.9) 1 (0.4)
Step I analgesics – n, % 138 (49.8) 100 (36.1) 25 (9.0) 13 (4.7) 1 (0.4)
Oral contraceptives – n, % 116 (41.9) 114 (41.2) 34 (12.3) 13 (4.7) 0 (0.0)